FILTER
FILTERED INTERVIEW RESULTS
Victor Swint
CEO, FORMULATED SOLUTIONS
"Rather than merely facilitating tech transfers, we aspire to lead the innovation charge for our clients."
Bart van Berkel
CEO, CURTEC
"Since the establishment of our facility in the US, we have felt the appreciation of the market in being able to have a local partner, especially in light of many companies trying to localize their supply chains."
John Patrick Oroho
PRESIDENT AND GENERAL MANAGER, RLDATIX LIFE SCIENCES
"RLDatix is a one-stop-shop offering comprehensive solutions to navigate critical operational and compliance challenges in the life sciences industry."
Roger Erickson
CEO AND FOUNDER, INTERBIOME
"We have large and growing volumes of missing diagnostics and therapeutics that never even go through the pharma pipeline, not to mention the growing number of neglected products languishing in the development pipeline."
Subodh Deshmukh and Ramesh Subramanian
CEO BIOLOGICS AND PRESIDENT DEVELOPMENT (SD) AND CCO (RS), ARAGEN LIFE SCIENCES
"We further strengthened our drug product service offerings by adding clinical capacity to drug product manufacturing."
Kristof De Smedt and Amardeep Chahal
GLOBAL BUSINESS UNIT DIRECTOR (KS) AND SENIOR VP MARKETING CORPORATE DEVELOPMENT (AC), COLD CHAIN TECHNOLOGIES (CCT)
"By focusing on performance, cost-effectiveness, compliance, sustainability, and visibility, we help our pharmaceutical customers achieve the optimal balance in their thermal packaging solutions."
Peter Schiemann
CEO, YMMUNOBIO
"We are dedicated to establishing proof of concept with our ADC targeting NPTXR."
Krishna Kanumuri
CEO AND MANAGING DIRECTOR, SAI LIFE SCIENCES
"I anticipate a continued trend of Western companies exploring India as an attractive manufacturing destination."
Tim Tyson
CHAIRMAN AND CEO, TRIRX PHARMACEUTICALS
"Great innovations and new medicines are emerging in the animal health space, especially in terms of biologics and monoclonal antibodies, and we saw great opportunities in this developing area."
Mike Radomsky
CEO, CMC PHARMACEUTICALS
"As biotech companies secure funding and advance their drug development programs, the demand for our services is expected to increase."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Latam North and Caribbean Mining 2025 - Digital Interactive
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
A convergence of high-commodity prices and low valuations, on the back of a structural deficit in exploration and discoveries, has set the perfect scene for increased M&A. The leverage is particularly high for acquisitions in Latam North and the Caribbean, where stocks do not command the high premiums of tier-one jurisdictions. But M&A is only a quick fix to the global resource replenishment crisis.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
